CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case
https://doi.org/10.17650/2782-3202-2022-2-3-36-42
Abstract
Currently, use of CDK4/6 inhibitors in combination with hormone therapy is approved for treatment of patients with advanced or metastatic breast cancer positive for estrogen and progesterone receptors and negative for human epidermal growth factor receptor 2 (HER2). In this clinical observation, analysis of the effectiveness of treatment of a patient with metastatic breast cancer of luminal A subtype is performed. The 1st line combination therapy was CDK4/6 inhibitors (ribociclib) and hormone therapy with aromatase inhibitors (letrozole) and analogues of gonadotropin-releasing hormone (goserelin) with concurrent bone-modifying denosumab therapy. Effectiveness of antitumor drug therapy administered for 7 months, and toxicity of the regimen were evaluated. Effectiveness of the selected combination treatment regimen was demonstrated and confirmed by clinical data, as well as results of laboratory and instrumental examinations. Adverse effects were controlled and managed with symptomatic therapy which allows to continue treatment using previously selected tactics.
About the Authors
D. A. Chekini
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Jennet A. Chekini
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081,
Bld. 2, 8 Trubetskaya St., Moscow 119991
E. K. Ibragimov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. Yu. Kolesnik
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. A. Fedenko
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
References
1. Cardoso F., Loibl S., Pagani O. et al. The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer. Eur J Cancer 2012;48(18):3355–77. DOI: 10.1016/j.ejca.2012.10.004
2. Avtomonov D.E., Parokonnaya A.A., Lyubchenko L.N. et al. Clinical and morphological characteristics and prognosis of BRCA-associated breast cancer in women of the reproductive age. Opukholy zhenskoy reproduktivnoy systemy = Tumors of female reproductive system 2012;1:20–4. (In Russ.).
3. Schepotin I.B., Zotov A.S., Lebedeva O.I. Breast cancer and woman’s reproductive function: mamma cancer in pregnant women and considerations of fertility preservation after treatment. Klinicheskaya onkologiya = Clinical Oncology 2012;1:59–63. (In Russ.).
4. Paluch-Shimon S., Pagani O., Partridge A.H. et al. Second international consensus guidelines for breast cancer in young women (BCY2). The Breast 2016;26:87–99. DOI: 10.1016/j.breast.2015.12.010
5. Kolyadina I.V., Poddubnaya I.V., van de Velde C.J.H. et al. Prognostic value of age for patients with early breast cancer. Sovremenniye tehnologii v meditsine = Modern Technologies in Medicine 2012;3:31–5. (In Russ.).
6. Rosenberg R., Levy-Schwartz R. Breast cancer in women younger than 40 years. Int J Fertil Womens Med 2003;48(5):200–5.
7. Assi H.A., Khoury K.E., Dbouk H. et al. Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 2013;5(Suppl 1):S2–8. DOI: 10.3978/j.issn.2072-1439.2013.05.24
8. Anders C.K., Johnson R., Litton J. et al. Breast cancer before age 40 years. Semin Oncol 2009;36(3):237–49. DOI: 10.1053/j.seminoncol.2009.03.001
9. Kim I., Park S., Hwang H. et al. Clinical significance of age at the time of diagnosis among young breast cancer patients. J Breast Cancer 2011;14(4):314–21. DOI: 10.4048/jbc.2011.14.4.314
10. Bharat A., Aft R.L., Gao F., Margenthaler J.A. Patient and tumor characteristics associated with increased mortality in young women (≤40 years) with breast cancer. J Surg Oncol 2009;100(3):248–51. DOI: 10.1002/jso.21268
11. Sidoni A., Cavaliere A., Bellezza G. et al. Breast cancer in young women: clinicopathological features and biological specificity. The Breast 2003;12(4):247–50. DOI: 10.1016/s0960-9776(03)00095-x
12. Aebi S., Gelber S., Castiglione-Gertsch M. et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? The Lancet 2000;355(9218):1869–74. DOI: 10.1016/s0140-6736(00)02292-3
13. Collins L.C., Marotti J.D., Gelber S. et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat 2012;131(3):1061–6. DOI: 10.1007/s10549-011-1872-9
14. Chollet-Hinton L., Anders C.K., Tse C.-K. et al. Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. Breast Cancer Res. 2016;18(1):79. DOI: 10.1186/s13058-016-0736-y
15. Tyulyandin S.A., Zhukova L.G., Koroleva I.A. et al. Practical recommendations for the drug treatment of breast cancer. Zlokachestvenniye opukholy: Prakticheskiye rekomendatsii RUSSCO = Malignant tumors: Practical Recommendations RUSSCO 2021;11(3s2):119–57. Available at: https://www.rosoncoweb.ru/standarts/RUSSCO/2021/2021-09.pdf. DOI: 10.18027/2224-5057-2021-11-3s2-09
Review
For citations:
Chekini D.A., Zeynalova P.A., Ibragimov E.K., Kolesnik A.Yu., Fedenko A.A. CDK4/6 inhibitors in combination with hormone therapy in clinical practice. Clinical case. MD-Onco. 2022;2(3):36-42. (In Russ.) https://doi.org/10.17650/2782-3202-2022-2-3-36-42
Views:
336
Email this article 